R(+) pramipexole dihydrochloride monohydrate ( DrugBank: Pramipexole )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 3 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00600873 (ClinicalTrials.gov) | August 2007 | 5/1/2008 | R(+)PPX High Dose Treatment of ALS | Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | NULL | Completed | 30 Years | 80 Years | Both | 10 | Phase 1/Phase 2 | United States |
2 | NCT00596115 (ClinicalTrials.gov) | October 2005 | 5/1/2008 | Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day | Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | University of Pittsburgh;University of Nebraska | Temporarily not available | 30 Years | 80 Years | Both | N/A | NULL | |
3 | NCT00140218 (ClinicalTrials.gov) | August 2005 | 30/8/2005 | R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: R(+) pramipexole dihydrochloride monohydrate | Bennett, James P., Jr., M.D., Ph.D. | University of Pittsburgh | Completed | 21 Years | 85 Years | Both | 30 | Phase 1/Phase 2 | United States |